Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer: early-phase trial registry
101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count
Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.
Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer
OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer recruits in line with its size-band peers.
101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.
-
Pancreatic Cancer research is mostly interventional.
237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 4 of 6
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT05141643
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Memorial Sloan Kettering Cancer Center
NCT04161755
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06168812
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Yale University
NCT03991962
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Andrew Hendifar, MD
NCT05336266
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04117087
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Lei Zheng
NCT05604560
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Bruno Bockorny
NCT05632328
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05642962
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05014776
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience
NCT03552718
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
University of Pennsylvania
NCT05057715
ZN-c3 + Gemcitabine in Pancreatic Cancer
Brandon Huffman, MD
NCT06015659
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Fox Chase Cancer Center
NCT04452357
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
NCT02955940
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT04137536
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT06141031
Creation of the BioBank, Early Detection and Discovery Biomarkers
Corewell Health East
NCT00901680
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Biospecimens for Identification of Diseases of the Pancreas.
University of Michigan
NCT01392027
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
NCIC Clinical Trials Group
NCT00026338
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
OSI Pharmaceuticals
NCT00040183
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00806611
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life
Johns Hopkins University
NCT01160367
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
Immunovia
NCT06947395
Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer
Wake Forest University Health Sciences
NCT01656044
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics
NCT02526017
OPTimizing Treatment Focused Genetic Testing IN Cancer
Dana-Farber Cancer Institute
NCT04066361
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
University of Pittsburgh
NCT01640522
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT04332653
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Astellas Pharma
NCT00902291
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis Pharmaceuticals
NCT01351103
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
NCT01373164
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT02791334
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
Ability Pharmaceuticals SL
NCT04431258
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Northwestern University
NCT01769248
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
Mauna Kea Technologies
NCT00779688
Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer
City of Hope Medical Center
NCT00902733
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
Wake Forest University Health Sciences
NCT00489515
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Dana-Farber Cancer Institute
NCT00831571
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT04247126
Prospective Study of Celiac Block Injection: 1 vs. 2
Indiana University
NCT00583479
Fatigue and Pancreas and Bile Duct Cancer Study
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00902759
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
Ohio State University Comprehensive Cancer Center
NCT01646697
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals
NCT02399137
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
KangLaiTe U
NCT00733850
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 114 |
| Phase 2 | 66 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer page
283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 101 Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.